Janssen to showcase robust oncology portfolio at ESMO 2018
The Janssen Pharmaceutical Companies of Johnson & Johnson will present updates from across its oncology portfolio at the European Society for Medical Oncology (ESMO) 2018 annual congress, taking place on 19-23 October in Munich, Germany. Phase 3 data from the SPARTAN study reporting health-related quality of life outcomes in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide will be included in a poster session, with a further poster session highlighting data for ZYTIGA® (abiraterone acetate) in metastatic hormone-sensitive prostate cancer. For erdafitinib in metastatic bladder cancer, a poster session will include an overview of the Phase 3 clinical trial design, and results from a Phase 2a study in advanced cholangiocarcinoma will be featured in a poster discussion.
“We are proud to share such robust data and across a range of tumor types at this year’s ESMO congress,” said Dr. Ivo Winiger-Candolfi M.D., Europe, Middle East and Africa Oncology Solid Tumor Therapy Area Lead, Cilag GmbH International. “We are particularly excited to present health-related quality of life data from the SPARTAN trial, results that were recently published in The Lancet Oncology. Transforming patient outcomes is a key commitment for us at Janssen, and helping patients maintain quality of life while on treatment can be as important as their clinical outcome.”
Company-sponsored abstracts to be presented at the meeting include:
|Abstract #804P||Health-Related Quality of Life (HRQoL) After Progressive Disease (PD) in SPARTAN: a Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)||
Poster display session
Monday 22 October
12:45 - 13:45
|Abstract #806P||Relationship Between Apalutamide (APA) Exposure and Metastasis-Free Survival (MFS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN||
Poster display session
Monday 22 October
Time: 12:45 - 13:45
|Abstract #797PD||LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT + abiraterone acetate and prednisone (AAP) or placebo (PBO)||
Poster discussion session - genitourinary tumours, prostate (ID 167)
Sunday 21 October
09:15 - 10:30
ICM - Room 14b
|Abstract #920TiP||Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients (pts) With Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRalt): the Phase 3 THOR Study||
Poster display session
Monday 22 October
|Abstract #624PD||Preliminary Results of a Phase2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)||
Poster discussion session: gastrointestinal, non-colorectal 1 (ID
Friday 19 October
15:45 - 17:20
Hall B3 - Room 21
|Abstract #834P||Interim Results of a Phase 1b Study of Niraparib plus Androgen Receptor-Targeted Therapy in Men with Metastatic Castration-Resistant Prostate Cancer||
Poster display session
Monday 22 October
|Abstract #1497P||JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non-Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results||
Poster display session
Saturday 20 October
|VELCADE ® (bortezomib)|
|Abstract # 1004O||Final Overall Survival Results of Frontline Bortezomib plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) vs R-CHOP in Transplantation-ineligible Patients (Pts) with Newly Diagnosed Mantle-Cell Lymphoma (MCL): A Randomized, Open-Label, Phase 3 (LYM3002) Study||
Proffered paper session
Sunday 21 October
11:00 – 11:15
About abiraterone acetate
Abiraterone acetate plus prednisone/prednisolone is the only approved oral therapy in metastatic prostate cancer that inhibits production of androgens (which fuel prostate cancer growth) at all three sources – the testes, adrenals and the tumour itself.1,2,3
In 2011, abiraterone acetate in combination with prednisone/prednisolone was approved by the European Commission (EC) for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
In December 2012, the EC granted an extension of the indication for abiraterone acetate permitting its use, in combination with prednisone or prednisolone, for the treatment of mCRPC, in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy for whom chemotherapy is not yet clinically indicated.3
In November 2017, the EC granted approval for broadening the existing marketing authorisation for abiraterone acetate plus prednisone/prednisolone for the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).3
Further information 3
The most common adverse reactions seen with abiraterone acetate plus prednisone/prednisolone observed in ≥10% of patients were peripheral oedema, hypokalaemia, hypertension urinary tract infection, and alanine aminotransferase increased and/or aspartate aminotransferase increased. Other important adverse reactions include cardiac disorders, hepatotoxicity, fractures, and allergic alveolitis. For a full list of side effects and for further information on dosage and administration, contraindications and other precautions when using abiraterone acetate plus prednisone/prednisolone please refer to the summary of product characteristics, which is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf
Apalutamide is an investigational, next-generation oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells. Apalutamide inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the AR; by stopping the AR from entering the cancer cells; and by preventing the AR from binding to the DNA of the cancer cell.4
Janssen has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) for apalutamide for the treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). ERLEADA™ (apalutamide) was approved in the United States for the treatment of patients with nmCRPC in February 2018.5
About erdafitinib 6
Erdafitinib is an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) inhibitor being studied in Phase 2 and Phase 3 clinical trials for the treatment of patients with locally advanced or metastatic urothelial cancer.7 FGFRs are a family of receptor tyrosine kinases, which can be activated by genetic alterations in a variety of tumor types, and these alterations may lead to increased tumor cell growth and survival.
Niraparib is an orally-administered highly-selective PARP inhibitor that is currently being studied for the treatment of patients with prostate cancer. In April 2016, Janssen entered a worldwide collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer. Niraparib is approved in Europe, Switzerland and the United States for the treatment of ovarian cancer and is marketed by TESARO.8
JNJ-61186372 (JNJ-372) is a fully human, IgG1 bispecific antibody that binds to both EGFR and cMET and is being developed by Janssen for the treatment of advanced non-small cell lung cancer.9
Bortezomib is the first in a specific class of medicines known as proteasome inhibitors. Proteasomes are present in all cells and play an important role in controlling cell function, growth and also how cells interact with other cells around them. Bortezomib reversibly interrupts the normal working of cell proteasomes, inducing the cancerous cells, to stop growing and die.10
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea. Follow us at http://www.twitter.com/janssenEMEA. Janssen-Cilag International N.V. and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
# # #
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including under “Item 1A. Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including under the caption “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
# # #
1 Hoy, SM. et al. Abiraterone Acetate: A review of its use in patients with metastatic castration-resistant prostate cancer drugs. Drugs 2013; 73:2077-2091.
2 Ritch, CR. Cookson, MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17;355:i4405. Doi: 10.1136/bmj.i4405.
3 ZYTIGA® summary of product characteristics (July 2018). Available at: https://www.ema.europa.eu/documents/product-information/zytiga-epar-product-information_en.pdf. Last accessed October 2018.
4 Clegg NJ, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494-1503.
5 FDA. FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint. Available at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm596768.htm. Last accessed October 2018.
6 Soria JC, et al. Poster presented at European Society for Medical Oncology conference, 7-11 October, 2016, Copenhagen, Denmark. Poster number: 781PD ClinicalTrials.Gov: NCT02365597
7 Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33:3401–3408. doi: 10.1200/JCO.2014.60.7341.
8 EMA. EPAR summary for the public Zejula (niraparib). Available at: https://www.ema.europa.eu/documents/overview/zejula-epar-summary-public_en.pdf. Last accessed October 2018
9 Immuno-oncology news. Available at: https://immuno-oncologynews.com/jnj-61186372/. Last accessed October 2018.
10 VELCADE EPAR summary for the public February 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000539/WC500048136.pdf. Last accessed October 2018
Phone: +353 85-744-6696
Office: 732 524-2955
Office: +1 732 524 3922
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41 | Tiedote
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42 | Tiedote
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00 | Tiedote
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07 | Tiedote
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 10:58 | Tiedote
Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme